July 11, 2019 - "Strong fundamentals fueling business development and pipeline progress"
Opioid addiction is a chronic medical condition with a number of associated co-morbidities which often requires life-long treatment. Although there is an increased focus on improving all aspects of care, as well as proactive measures in place to tackle the opioid crisis in the US, there is still an urgent medical need for more efficient treatments covering all phases of opioid addiction.
October 17 2019 - On October 24, 8 am, the Q3 2019 Interim Report will be announced. The same day at 2 pm investors, analysts and media are invited to listen to Nikolaj Sørensen CEO and Joseph DeFeo CFO presenting the report and answering questions about the latest development and the way going forward.
Orexo has a strong history of developing new products approved in markets all over the world. In order to ensure a continued inflow of new improved drugs, the work at the development department in Uppsala, Sweden, has intensified. Filling an unmet need among healthcare professionals and patients is the key in the work of developing new innovative products for treatment of opioid addiction in all phases.
AUGUST 21, 2019 - Orexo will together with its partner GAIA AG develop and commercialize a new digital therapy to increase access and improve treatments of Opioid Use Disorder. Why digital therapies, why now and why together with GAIA? Nikolaj Sørensen, CEO, answers this questions in the latest version of Orexo Our View.